BIOMARKER:

RUNX1 mutation

Entrez ID:

Related biomarkers:

‹

›

RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C2 – Inclusion Criteria
RUNX1 mutation RUNX1 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	venetoclax + RO5503781 Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	LY3009120 Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine + clofarabine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	cytarabine + cladribine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	decitabine + clofarabine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	decitabine + cladribine Sensitive: C3 – Early Trials
RUNX1 mutation RUNX1 mutation	Acute Myelogenous Leukemia AML	tagraxofusp Sensitive: D – Preclinical